Navigation Links
Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
Date:3/10/2008

NEW YORK, MARCH 6, 2008 A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity. While previous reports evaluating the cardiac effects of breast cancer treatments including trastuzumab and anthracyclines have shown an acceptable safety margin, the new study demonstrates an even lower risk of cardiac toxicity when standard doses of these drugs are administered more frequently over time a treatment plan called dose-dense, which has previously been shown to be a more effective anti-cancer approach.

The researchers used a dose-dense regimen of doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan or Neosar) followed by paclitaxel (Taxol) and found that the regimen when given every two weeks instead of three pairs safely with trastuzumab, a drug that is used to treat breast cancer in women whose tumors contain the protein receptor called HER2.

According to the findings, only 1.4 percent (one patient) of the 70 early-stage breast cancer patients treated with this regimen experienced congestive heart failure after 28 months of follow-up. This rate of cardiac toxicity is lower than the 4 percent threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment with the use of trastuzumab.

The studys authors concluded that this dose-dense regimen combined with trastuzumab is a safe and effective way to treat women with early-stage HER2-positive breast cancer in the adjuvant setting and there is no need to forgo the use of this regimen because trastuzumab is also being administered.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Moderate alcohol consumption in middle age can lower cardiac risk
2. CardiacQA Surpasses 20,000 Client Generated Nuclear Cardiology Reports
3. Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results
4. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
5. Cardiac Science Corporation Selects Colubris Networks Wireless Solution for its Portable Electrocardiograph
6. $4 million award to improve detection of acute kidney injury after cardiac surgery
7. Cardiac Science to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
8. Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
9. Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanced Cardiac Scanner
10. Gene predicts heart attack response and cardiac damage
11. Delray Beach Mayor Commemorates Diagnostic Centers of America (DCA) $2 Million Purchase from Siemens to Become Only Medical Facility in South Florida with Worlds Most Advanced Cardiac Scanner.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Conditions were ideal ... Cove Island Park on Sunday, with sunny skies, a light breeze and temperatures in ... $33,000. , The 5k Run and Walk and 1-mile walk were held ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: ... Financial Officer, will present at the Deutsche Bank 41st Annual ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... the Presentations and Webcasts section of Shire,s Investor website at ... be available on this same website for approximately 90 days. ...
Breaking Medicine Technology: